New recommendations guided by CVOTs include an early consideration of CV risk and preference for an agent with proven CV benefit as a first-add on to metformin in an atherosclerotic CVD setting (preferring empagliflozin or liraglutide) [1,2,3, 6] or an SGLT2 inhibitor as a first add-on to metformin in a HF setting [1,2,3, 5] (Fig
adults are interested in trying a GLP-1 for weight loss (KFF) GLP-1 prescriptions have risen over 300% in the past two years (Trilliant Health) Interest is highest among working-age employees your covered population For employers, it presents a familiar but urgent challenge: how do we provide access to an in-demand health benefit without wrecking the plan budget
At ATX Infusion and Wellness, our approach to weight loss includes not just reducing body fat, but supporting whole-body healthincluding the maintenance of lean muscle
What's new and what's kind of come to the forefront, which is part of the decision-making process, is really around whether they're going to extend that coverage to weight loss, right
The medication's mechanism of slowing gastric emptying and reducing appetite commonly leads to gastrointestinal symptoms, particularly during dose initiation and escalation
Li, L.-F